The first federal appellate decision on fair use in AI training goes against the AI developer.
A licensee holding all substantial rights can sue without joining its state-university licensor.
The en banc denial leaves the April 2026 antibody enablement ruling and $177 million verdict in place.
A precedential USPTO decision addresses how obviousness-type double patenting applies to related patents, even when the challenged application would expire first.
